


JONES, DAVID T. W., PH.D

GENERAL INFORMATION

	Group Leader Hopp Children's Cancer Center at the NCT Heidelberg (KITZ) German Cancer Research Center (DKFZ), Pediatric Glioma Research Group Im Neuenheimer Feld 280, 69120 Heidelberg, Germany	A02
---	--	-----

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2001-2004	BA in Natural Sciences, University of Cambridge

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2005-2009	PhD in Molecular Genetics of Brain Tumors, University of Cambridge. Supervisor: Prof V. Peter Collins

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2016-present	Group Leader – Pediatric Glioma Genomics, German Cancer Research Center (DKFZ)
2012-2016	Senior PostDoc/Subgroup Leader – Division of Pediatric Neurooncology, DKFZ
2010-2012	PostDoc – Division of Pediatric Neurooncology, DKFZ
2009-2010	PostDoc – University of Cambridge

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2015-present	Member, Innovative Therapies for Childhood Cancer (ITCC) Biology Committee
2011-present	Member, SIOG Low-grade glioma & High-grade glioma working groups
2014	Kind-Philipp Prize for research in the field of Pediatric Oncology
2013	Waltraud-Lewenz Award for research in the field of Cancer Risk Factors & Prevention <i>or</i> Diagnostics & Experimental Therapeutics

SELECTED PUBLICATIONS

- Capper D*, Jones DTW*, Sill M*, Hovestadt V*, et al., and von Deimling A, Pfister SM. DNA methylation-based classification of central nervous system tumours. **Nature** 2018;555(7697):469-474
- Bender S, Gronych J, Warnatz H-J, Hutter B, et al., and Pfister SM*, Lichter P*, Jones DTW*. Recurrent MET fusion genes represent a druggable target in paediatric glioblastoma. **Nat Med** 2016;22(11):1314-1320
- Hovestadt V*, Jones DTW*, et al., and Radlwimmer B, Pfister SM, and Lichter P. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. **Nature** 2014;510(7506):537-41
- Kool M, Jones DTW, et al., and Wechsler-Reya RJ, Lichter P, Pfister SM. Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. **Cancer Cell** 2014;25(3):393-405
- Jones DTW*, Hutter B*, Jäger N*, et al., and Eils R, Lichter P and Pfister SM. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. **Nat Genet** 2013;45(8):927-32

6. Sturm D, Witt H, Hovestadt V, Khuong Quang D-A, Jones DTW, et al., and Plass C, Jabado N & Pfister SM. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. **Cancer Cell** 2012;22(4):425-37
7. Jones DTW*, Jäger N*, et al., and Eils R, Pfister SM & Lichter P. Dissecting the Genomic Complexity Underlying Medulloblastoma. **Nature** 2012;488(7409):100-5
8. Schwartzentruber J*, Korshunov A*, Liu XY*, Jones DTW, et al., and Majewski J, Pfister SM, Jabado N. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. **Nature** 2012;482(7384):226-31
9. Rausch T*, Jones DTW*, Zapatka M*, Stütz AM*, et al., and Lichter P, Pfister SM & Korbel JO. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. **Cell** 2012;148(1-2):59-71
10. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K & Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. **Cancer Res** 2008;68(21):8673-8677

PATENTS

- Patent held: “Mutations of histone proteins associated with proliferative disorders” (WO 2013075237 A1)
- Patent pending: “DNA methylation-based method for classifying tumor species” (WO 2016142533 A1)